CLINICAL_TRIALS ClinicalTrials.gov record update

Relative Efficacy of Loteprednol (Lotemax®) vs. Loteprednol/Tobramycin (Zylet®) in Treatment of Chronic Ocular Surface Inflammation Associated With Meibomian Gland Dysfunction (MGD)/Posterior Blepharitis

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01456780
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:29.132244+00:00
Published At: 2017-06-19T00:00:00+00:00
Record Updated At: 2017-08-01
Results Posted At: 2017-06-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Meibomian Gland Dysfunction", "Posterior Blepharitis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2017-08-01"
protocolSection.identificationModule.nctId: "NCT01456780"
protocolSection.identificationModule.officialTitle: "Relative Efficacy of Loteprednol (Lotemax\u00ae) vs. Loteprednol/Tobramycin (Zylet\u00ae) in Treatment of Chronic Ocular Surface Inflammation Associated With Meibomian Gland Dysfunction (MGD)/Posterior Blepharitis"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2017-06-19"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.